CD7 is an attractive target for chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory T-cell acute lymphoblastic leukemia (ALL). Supportive results of first-in-human studies of base ...
A cutting-edge therapy using base-edited immune cells is offering a major breakthrough for patients with one of the toughest forms of blood cancer, T-cell acute lymphoblastic leukaemia. By precisely ...
Researchers discovered a way to keep T cells from wearing out during the fight against cancer, and the approach could make immune-based treatments far more powerful. They found that tumors use a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results